Cara Therapeutics price target raised to $29 from $25 at Canaccord Canaccord raised its price target on Cara Therapeutics to $29 from $25 on the CRS-45's potential in adjunct post-operative pain relief. The firm expects positive Phase 3 data in the second half of 2015 and could have potential US sales of $750M. Shares are Buy rated.
News For CARA From The Last 14 Days
Check below for free stories on CARA the last two weeks.